AstraZeneca: Bridging the Prilosec Earnings Gap
AstraZeneca appears to have navigated the integration process without much of the turmoil seen in other mergers. As part of that integration, the company created a new, centralized sales and marketing infrastructure intended to transform two mid-size European companies into a commercial global power. That new organization will soon confront the company's most immediate challenge: dealing with the genericization of the world's biggest drug, Prilosec. Whether AstraZeneca can meet that challenge will turn largely on the extent to which two late-stage drug candidates, Nexium and Crestor, can fill the Prilosec void. They'll require a commercialization effort far beyond that attempted by the former Astra or Zeneca.
You may also be interested in...
Generic firms are attacking drug patents--even before they expire--with increasingly clever legal strategies. And it looks like the FDA may be helping them do it.
At Windhover's annual Marketing Pharmaceutical Innovation (MPI) conference in November, industry executives wrestled with an emerging dilemma -- how to win managed care's support for drugs that exhibit only minor improvements to existing products, while new over-the-counter (OTC) options surface.
A combination of successful pricing and marketing tactics in competitive European markets such as Germany have helped AztraZeneca's blockbuster anti-ulcer franchise weather the generic storm. But the US could tell a different story.